Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Rhea-AI Summary

Advanced Biomed (Nasdaq: ADVB) will effect a 1-for-20 reverse stock split at the open of Nasdaq on February 20, 2026 to regain compliance with Nasdaq Listing Rule 5550(a)(2).

The board approved the split on January 30, 2026 after shareholder written consent on January 12, 2026. Post-split shares outstanding will change from 27,290,710 to approximately 1,364,536, and the security will trade under the same symbol ADVB with a new CUSIP 00752P203.

Positive

• Aims to regain Nasdaq compliance with $1.00 minimum bid requirement
• Immediate reduction to ~1.36M issued shares post-split
• Board-approved implementation on a defined effective date

Negative

• Reverse split may reduce trading liquidity and average daily volume
• Perception risk: reverse split typically follows a sub-$1 share price
• CUSIP change could cause short-term trading or settlement frictions

News Market Reaction

-10.69% 27.9x vol

16 alerts

-10.69% News Effect

+43.5% Peak Tracked

-13.9% Trough Tracked

-$779K Valuation Impact

$7M Market Cap

27.9x Rel. Volume

On the day this news was published, ADVB declined 10.69%, reflecting a significant negative market reaction. Argus tracked a peak move of +43.5% during that session. Argus tracked a trough of -13.9% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $779K from the company's valuation, bringing the market cap to $7M at that time. Trading volume was exceptionally heavy at 27.9x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Reverse split ratio: 1-for-20 Shares outstanding pre-split: 27,290,710 shares Shares outstanding post-split: 1,364,536 shares +5 more

8 metrics

Reverse split ratio 1-for-20 Ratio for share consolidation effective February 20, 2026

Shares outstanding pre-split 27,290,710 shares Total issued and outstanding common shares before reverse split

Shares outstanding post-split 1,364,536 shares Approximate issued and outstanding common shares after reverse split

Nasdaq minimum bid $1.00 per share Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement

Net income $6.47M Six months ended December 31, 2025 (driven by gain on HK sale)

Equity line capacity $25,000,000 Maximum common stock issuable under equity line of credit

Private placement shares 4,000,000 shares at $0.062 Shares sold January 28, 2026 for total proceeds of $248,000

Commitment fee shares 1,650,710 shares for $500,000 Shares issued January 30, 2026 as equity line commitment fee

Market Reality Check

Price: $0.2266 Vol: Volume 7,309 is well belo...

low vol

$0.2266 Last Close

Volume Volume 7,309 is well below the 20-day average of 39,488 (relative volume 0.19x). low

Technical Shares trade below the 200-day MA of 0.57, with the last price at 0.2401 and near the 52-week low of 0.2111.

Peers on Argus

ADVB showed a modest -0.62% move while peers were mixed: names like PRPH were up...

1 Down

ADVB showed a modest -0.62% move while peers were mixed: names like PRPH were up 16.77%, ISPC and BIAF also gained, whereas MYNZ and XWEL fell. Peer momentum flags only MYNZ with a sharp downside move, suggesting ADVB’s reverse split news is company-specific rather than a broad sector reaction.

Historical Context

3 past events · Latest: Feb 13 (Positive)

Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Feb 13	Feasibility study deal	Positive	+1.1%	120‑case IRB‑approved feasibility study for A+PerfusC with Chi‑Mei Medical.
Dec 30	Subsidiary divestiture	Neutral	+1.5%	Sale of Hong Kong subsidiary and shift of clinical trials to Taiwan unit.
Sep 19	Product launch	Positive	-17.2%	Launch of A+PerfusC 3D cell culture platform targeting global 3D culture market.

Pattern Detected

Recent news reactions have been mixed: operational and collaboration updates sometimes led to modest gains, while a major product launch coincided with a double‑digit decline.

Recent Company History

Over the last several months, ADVB has alternated between strategic and operational updates. A September 19, 2025 launch of its A+PerfusC™ 3D cell culture platform saw the stock fall 17.18%, despite the product’s positioning in a growing market. A December 30, 2025 divestiture of its Hong Kong subsidiary and a February 13, 2026 120‑case feasibility study announcement both drew small positive moves. Today’s reverse split follows this pattern of capital‑markets oriented steps alongside ongoing platform development.

Market Pulse Summary

The stock dropped -10.7% in the session following this news. A negative reaction despite the formal ...

Analysis

The stock dropped -10.7% in the session following this news. A negative reaction despite the formal compliance step would fit a pattern where capital‑markets moves and prior dilutive financings, such as the 4,000,000 shares at $0.062, weigh on confidence. The reverse split cuts outstanding shares from 27,290,710 to about 1,364,536 but does not change underlying operations, and filings highlight ongoing cash use and going‑concern risk. Past product news has even seen selling, suggesting investors remain cautious.

Key Terms

reverse stock split, cusip, regulation s, form 25-nse, +1 more

5 terms

reverse stock split financial

"today announced a reverse stock split of the Company’s issued and outstanding"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

cusip technical

"under the same symbol “ADVB” but under a new CUSIP number, 00752P203."

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

regulation s regulatory

"private placement relying on exemptions under Section 4(a)(2) and Regulation S."

Regulation S is a set of rules that allows companies to sell securities (like shares or bonds) to investors outside the United States without having to follow all U.S. securities laws. It matters because it makes it easier for companies to raise money from international investors while still complying with U.S. regulations.

form 25-nse regulatory

"stayed any suspension and the filing of a Form 25-NSE while a Nasdaq"

Form 25‑NSE is an official filing used to notify the stock exchange that a company’s securities are being removed from trading on that exchange, similar to handing in a key when a shop closes. Investors care because removal ends public trading on that venue, often cutting liquidity and making it harder to buy or sell shares, which can affect a stock’s price and how quickly investors can access cash or exit positions.

equity line of credit financial

"a $25M equity line of credit agreement with an institutional investor"

An equity line of credit is a loan that allows homeowners to borrow money against the value of their property, similar to having a flexible credit card secured by their home. It matters to investors because it provides a way for property owners to access cash for various needs, which can influence real estate markets and overall economic activity. This type of credit offers ongoing borrowing capacity, making it a valuable financial tool for those with significant property equity.

AI-generated analysis. Not financial advice.

Tainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced a reverse stock split of the Company’s issued and outstanding common stock at a ratio of 1 for 20 shares (the “Reverse Split”), which will take effect at the open of The Nasdaq Stock Market (“Nasdaq”) on February 20, 2026.

In accordance with Section 78.320.2 of the Nevada Revised Statutes, on January 12, 2026, the holders of a majority of the outstanding voting power of the Company approved by written consent a reverse stock split of the Company’s issued and outstanding shares of common stock, at a ratio of not less than 1 for 2 and not more than 1 for 100 shares, with the final ratio and timing of implementation to be determined by the board in its sole discretion, and authorized the board to effect such reverse stock split at any time thereafter. On January 30, 2026, the board approved implementation of the reverse stock split at a ratio of 1 for 20 shares.

The objective of the reverse split is to enable the Company to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed on The Nasdaq Capital Market to evidence a minimum bid price of $1.00 per share.

Upon the open of trading on February 20, 2026, the Company’s common stock will begin trading on a reverse split-adjusted basis, under the same symbol “ADVB” but under a new CUSIP number, 00752P203.

As a result of the reverse split, each 20 shares of common stock with a par value of US$0.001 will automatically combine and convert into one issued and outstanding share of common stock with the same par value of US$0.001. The reverse split will affect all stockholders uniformly and will not alter any stockholder's percentage ownership interest in the Company, except for minimal changes that may result from the treatment of fractional shares. No action is required by stockholders holding their shares through a brokerage account.

No fractional shares will be issued to any stockholders in connection with the reverse split, and each stockholder will be entitled to receive one full share of common stock in the Company in lieu of the fractional share that would have resulted from the reverse split.

At the time the share consolidation is effective, the Company’s total issued and outstanding common shares will change from 27,290,710 common shares to approximately 1,364,536 common shares. The Company’s authorized shares will remain unchanged.

About Advanced Biomed Inc.

Advanced Biomed Inc. is a Nevada corporation specializing in innovative biomedical technologies for cancer detection and precision medicine.

Operating through the subsidiary in Taiwan, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its portfolio includes devices, biochips, and designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for future global expansion.

For more information, please visit: www.advanbiomed.com.

Forward‑Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the documents filed with the United States Securities and Exchange Commission (the “SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email: info@advbiomedicine.com
invest@advbiomedicine.com

FAQ

What is the effective date of Advanced Biomed's 1-for-20 reverse split (ADVB)?

The reverse split takes effect at the open of Nasdaq on February 20, 2026. According to the company, trading will resume on a reverse split-adjusted basis under the same symbol ADVB with a new CUSIP 00752P203.

How will the 1-for-20 reverse split change ADVB's outstanding shares?

Outstanding shares will change from 27,290,710 to approximately 1,364,536. According to the company, each 20 pre-split shares will combine into one post-split share.

Do ADVB shareholders need to act for the February 20, 2026 reverse split?

No action is required for shareholders holding shares through brokerage accounts. According to the company, brokers will adjust holdings automatically for the split.

Will Advanced Biomed issue fractional shares after the reverse split for ADVB?

No fractional shares will be issued; shareholders will receive one full share in lieu of fractional amounts. According to the company, this treatment applies uniformly to all stockholders.

Why is Advanced Biomed (ADVB) implementing a 1-for-20 reverse stock split?

The company says the objective is to enable regaining compliance with Nasdaq Listing Rule 5550(a)(2) requiring a minimum bid price of $1.00. The board approved the split to address that requirement.